These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34645316)

  • 1. Use of upadacitinib in the treatment of psoriatic arthritis.
    Ross Y; Magrey M
    Immunotherapy; 2021 Dec; 13(18):1549-1554. PubMed ID: 34645316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
    McInnes IB; Anderson JK; Magrey M; Merola JF; Liu Y; Kishimoto M; Jeka S; Pacheco-Tena C; Wang X; Chen L; Zueger P; Liu J; Pangan AL; Behrens F
    N Engl J Med; 2021 Apr; 384(13):1227-1239. PubMed ID: 33789011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upadacitinib for the treatment of adult patients with active psoriatic arthritis.
    Marchesoni A; Citriniti G; Girolimetto N; Possemato N; Salvarani C
    Expert Rev Clin Immunol; 2024 May; 20(5):423-434. PubMed ID: 38155531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.
    Baraliakos X; Ranza R; Östör A; Ciccia F; Coates LC; Rednic S; Walsh JA; Douglas K; Gao T; Kato K; Song IH; Ganz F; Deodhar A
    Arthritis Res Ther; 2023 Apr; 25(1):56. PubMed ID: 37038159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
    Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
    Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
    Burmester GR; Winthrop K; Blanco R; Nash P; Goupille P; Azevedo VF; Salvarani C; Rubbert-Roth A; Lesser E; Lippe R; Lertratanakul A; Mccaskill RM; Liu J; Ruderman EM
    Rheumatol Ther; 2022 Apr; 9(2):521-539. PubMed ID: 34970731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study.
    McInnes IB; Kato K; Magrey M; Merola JF; Kishimoto M; Pacheco-Tena C; Haaland D; Chen L; Duan Y; Zueger P; Liu J; Lippe R; Pangan AL; Behrens F
    RMD Open; 2021 Oct; 7(3):. PubMed ID: 34663636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials.
    Muensterman E; Engelhardt B; Gopalakrishnan S; Anderson JK; Mohamed MF
    Clin Transl Sci; 2022 Jan; 15(1):267-278. PubMed ID: 34464029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating upadacitinib for the treatment of psoriatic arthritis.
    Akpabio A; Adebajo A
    Expert Opin Pharmacother; 2022 Feb; 23(2):169-173. PubMed ID: 35014922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upadacitinib for the treatment of rheumatoid arthritis.
    Serhal L; Edwards CJ
    Expert Rev Clin Immunol; 2019 Jan; 15(1):13-25. PubMed ID: 30394138
    [No Abstract]   [Full Text] [Related]  

  • 11. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
    Mease PJ; Lertratanakul A; Anderson JK; Papp K; Van den Bosch F; Tsuji S; Dokoupilova E; Keiserman M; Wang X; Zhong S; McCaskill RM; Zueger P; Pangan AL; Tillett W
    Ann Rheum Dis; 2021 Mar; 80(3):312-320. PubMed ID: 33272960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK1 selective inhibitors for the treatment of spondyloarthropathies.
    White JPE; Coates LC
    Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii39-ii44. PubMed ID: 33950224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials.
    McInnes IB; Ostor AJK; Mease PJ; Tillett W; Baraliakos X; de Vlam K; Bessette L; Lippe R; Maniccia A; Feng D; Gao T; Zueger P; Saffore C; Kato K; Song IH; Deodhar A
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35332058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
    Keeling S; Maksymowych WP
    Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials.
    Mysler E; Burmester GR; Saffore CD; Liu J; Wegrzyn L; Yang C; Betts KA; Wang Y; Irvine AD; Panaccione R
    Adv Ther; 2024 Feb; 41(2):567-597. PubMed ID: 38169057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Charles-Schoeman C; Choy E; McInnes IB; Mysler E; Nash P; Yamaoka K; Lippe R; Khan N; Shmagel AK; Palac H; Suboticki J; Curtis JR
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37945286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC.
    Coates LC; Garrood T; Gullick N; Helliwell P; Kent T; Marks J; Tillett W; Kaur-Papadakis D; Tahir H; van Haaren S; McInnes I
    Rheumatology (Oxford); 2022 Dec; 62(1):e1-e3. PubMed ID: 35799375
    [No Abstract]   [Full Text] [Related]  

  • 18. Upadacitinib in nail psoriasis: a case report.
    Wang N; Yang Q; Liu Y; Liu H
    J Dermatolog Treat; 2023 Dec; 34(1):2246604. PubMed ID: 37661936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
    Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials.
    Mease P; Kavanaugh A; Gladman D; FitzGerald O; Soriano ER; Nash P; Feng D; Lertratanakul A; Douglas K; Lippe R; Gossec L
    Rheumatol Ther; 2022 Aug; 9(4):1181-1191. PubMed ID: 35606663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.